⚡ Flash Summary

Ferozsons Laboratories Limited will hold its Annual General Meeting (AGM) on October 25, 2025, to discuss and approve the financial statements for the year ended June 30, 2025. A key agenda item is the approval of a final cash dividend of 40% (Rs. 4 per share) as recommended by the Board of Directors. The meeting will also address related party transactions conducted during the financial year 2024-25 and appoint auditors for the year ending June 30, 2026. Shareholders can attend in person or via video link and are required to register in advance following specific procedures outlined in the notice.

📌 Key Takeaways

• 📅 AGM Date: October 25, 2025.
• 📍 Location: Blue Lagoon, Rawalpindi, and via video-link.
• ✅ Agenda: Approval of financial statements for the year ended June 30, 2025.
• 💰 Dividend: Final cash dividend of 40% (Rs. 4 per share) proposed.
• 🤝 Related Party Transactions: Approval sought for transactions in FY 2024-25 and authorization for future transactions.
• 🧑‍⚖️ Auditor Appointment: Appointment of auditors for the year ending June 30, 2026.
• 🛑 Book Closure: Share transfer books closed from October 18 to October 25, 2025.
• 🖥️ Video Link: Shareholders can participate via video link with prior registration.
• 🆔 CNIC: Members requested to submit CNIC copies for registration.
• 🏦 Electronic Dividend Mandate: Shareholders to provide bank account details for electronic dividend payments.
• 📃 Proxy: Members can appoint a proxy to attend and vote on their behalf.
• ✉️ Postal Ballot: Members can vote via postal ballot on special business items.
• 🌐 Website: Financial statements available on the company’s website (www.ferozsons-labs.com).
• ⚠️ ATL: Members should ensure they are on the Active Tax Payers’ List to avoid higher withholding tax on dividends.
• 🏢 CDC Account: Encouragement to transfer physical shares to CDC account.

🎯 Investment Thesis

Based on the AGM notice alone, a neutral HOLD recommendation is appropriate. The proposed dividend is positive, but a comprehensive analysis of the financial statements and related party transactions is necessary before making a buy or sell recommendation. A price target cannot be determined without further financial information.